# US 2007/0099275 A1 · Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2007/0099275 A1
- Document ID: US20070099275A1
- Status: Published application
- Kind: A1
- Application number: 11/591,649
- Filed: 2006-11-01
- Published: 2007-05-03
- Earliest claimed: 2005-11-03
- Assignees: Dialean, Ltd.
- Inventors: Liat Mintz
- Web page: https://patentgrep.com/patent/US20070099275A1

## CPC

- C07K 14/575: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2333/575: Hormones
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention concerns ten novel variants of alternative splicing of the hormonal imbalance related genes.

## Claims

### Claim 1

An isolated nucleic acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and a complement thereof.

### Claim 2 (depends on 1)

An isolated nucleic acid sequence having 90% identity to the isolated nucleic acid sequence of claim 1.

### Claim 3 (depends on 1)

An isolated nucleic acid fragment comprising at least a 15 contiguous base pair segment of the isolated nucleic acid sequence of claim 1.

### Claim 4 (depends on 1, 3)

The isolated nucleic acid fragment of claim 3 comprising a 15-30 contiguous base pair segment of the isolated nucleic acid sequence of claim 1.

### Claim 5 (depends on 3)

A primer comprising the isolated nucleic acid fragment of claim 3.

### Claim 6 (depends on 3)

A probe comprising the isolated nucleic acid fragment of claim 3.

### Claim 7 (depends on 1)

The isolated nucleic acid sequence of claim 1, wherein at least one preferred codon replaces at least one codon of said sequence.

### Claim 8 (depends on 1)

An expression vector comprising the isolated nucleic acid sequence of claim 1, said sequence operably-linked to control elements for the expression of said sequence in a host cell.

### Claim 9 (depends on 8)

A host cell transfected with the expression vector of claim 8.

### Claim 10

An antisense oligonucleotide comprising a 10-40 contiguous base pair segment of a reverse complement of a nucleic acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19.

### Claim 11

An isolated amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38.

### Claim 12 (depends on 11)

An isolated amino acid sequence having 90% identity to the isolated amino acid sequence of claim 11.

### Claim 13

An isolated antibody which specifically binds to an epitope on an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38.

### Claim 14

An isolated peptide comprising at least a 10 contiguous amino acid segment of an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38.

### Claim 15 (depends on 14)

The isolated peptide of claim 14 comprising a 10-20 contiguous amino acid segment of the amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38.

### Claim 16

A method for detecting the presence of at least one variant nucleic acid sequence of hormonal imbalance related genes in a biological sample comprising the steps of:
(a) hybridizing to nucleic acid material of the biological sample an isolated nucleic acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and a complement thereof; and
(b) detecting a hybridization complex produced by step (a); wherein the presence of the hybridization complex correlates with the presence of at least one variant nucleic acid sequence in the biological sample.

### Claim 17

A method for determining the level of variant nucleic acid sequences in a biological sample comprising the steps of:
(a) hybridizing to nucleic acid material of the biological sample an isolated nucleic acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and a complement thereof;
(b) determining the amount of hybridization complexes produced by step (a); and
(c) normalizing the amount of hybridization complexes to provide a level of variant nucleic acid sequences in the biological sample.

### Claim 18

A method for determining the ratio between the level of a nucleic acid sequence of an hormonal imbalance related gene variant in a first biological sample and a variant produced by alternative splicing in a second biological sample comprising the steps of:
(a) determining the level of a first nucleic acid sequence of an hormonal Imbalance related gene variant in a first biological sample;
(b) determining the level of a second nucleic acid sequence of an alternative splicing form of the variant in a second biological sample; and
(c) comparing the levels obtained in step (a) and step (b) to give a ratio.

### Claim 19 (depends on 18)

The method of claim 18, wherein the first biological sample and the second biological sample are the same sample.

### Claim 20 (depends on 18)

The method of claim 18, wherein the first nucleic acid sequence and the second nucleic acid sequence are mRNA transcripts.

### Claim 21 (depends on 20)

The method of claim 20, wherein the first nucleic acid sequence and the second nucleic acid sequence are deposed on a nucleic acid chip.

### Claim 22

A method for the identification of compounds capable of affecting the binding affinity of hormonal imbalance related proteins to the receptors of said proteins comprising the steps of:
(a) providing an amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, and SEQ ID NO:38;
(b) contacting a candidate compound with the amino acid sequence in the presence of at least one receptor of an hormonal Imbalance related gene;
(c) determining the effect of the candidate compound on the binding of the amino acid sequence to the at least one receptor; and
(d) selecting a compound capable of affecting the binding affinity of hormonal Imbalance related proteins to the receptors of said proteins.

### Claim 23

A method for determining the ratio between the level of an hormonal imbalance related protein variant in a first biological sample and a variant produced by alternative splicing in a second biological sample comprising the steps of:
(a) determining the level of a first amino acid sequence of an hormonal imbalance related gene variant in a first biological sample;
(b) determining the level of a second amino acid sequence of an alternative splicing form of the variant in a second biological sample; and
(c) comparing the levels obtained in step (a) and step (b) to give a ratio.

### Claim 24

A method of detecting a specific hormonal imbalance related nucleic acid sequence by polymerase chain reaction comprising the steps of:
(a) amplifying a specific hormonal imbalance related nucleic acid sequence with a primer pair, wherein at least one of the primers comprises an at least 15 contiguous base pair segment of a nucleic acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, and a complement thereof; and
(b) detecting the nucleic acid product of step (a).

### Claim 25

A method of treating hormonal imbalance comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition comprising:
(a) an isolated amino acid sequence selected from the group consisting of SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, and a peptide comprising at least a 10 contiguous amino acid segment thereof;
and
(b) a carrier.
